Predicting Parkinson disease in the community using a nonmotor risk score

European Journal of Epidemiology

Volumn 31, Issue 7, 2016, Pages 679-684

  Darweesh, Sirwan K L ^a   Koudstaal, Peter J ^a   Stricker, Bruno H ^a,b   Hofman, Albert ^a   Steyerberg, Ewout W ^a   Ikram, M Arfan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Inspectorate for Health Care   (Netherlands)

Author keywords

Parkinson disease; Population based; Risk factors; Risk prediction

Indexed keywords

ALCOHOL; ANTIPARKINSON AGENT; LAXATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL FEATURE; COFFEE; CONSTIPATION; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DRINKING; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NETHERLANDS; NEUROLOGIC DISEASE ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; POPULATION RESEARCH; PREDICT PD RISK SCORE; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; SMOKING; COHORT ANALYSIS; HEALTH SURVEY; NEUROPSYCHOLOGICAL TEST; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; QUESTIONNAIRE; REPRODUCIBILITY; STANDARDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SURVEYS AND QUESTIONNAIRES;

EID: 84959177995     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-016-0130-1     Document Type: Article

References (18)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–35. doi:10.1016/S1474-4422(06)70471-9.
2. Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in Parkinson’s disease. Mov Disord. 2013;28(1):86–95. doi:10.1002/mds.24997.
3. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012;72(6):893–901. doi:10.1002/ana.23687.
4. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. PREDICT-PD: identifying risk of Parkinson’s disease in the community: methods and baseline results. J Neurol Neurosurg Psychiatry. 2014;85(1):31–7. doi:10.1136/jnnp-2013-305420.
5. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7(4):403–22.
6. Hofman A, Brusselle GG, Darwish Murad S, et al. The Rotterdam Study: 2016 objectives and design update. Eur J Epidemiol. 2015;30(8):661–708. doi:10.1007/s10654-015-0082-x.
7. de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson’s disease in the elderly: the Rotterdam Study. Neurology. 1995;45(12):2143–6.
8. Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining?: trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78(19):1456–63. doi:10.1212/WNL.0b013e3182553be6.
9. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology. 2004;63(7):1240–4.
10. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128–38. doi:10.1097/EDE.0b013e3181c30fb2.
11. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. doi:10.2307/2670170.
12. Uno H, Cai TX, Pencina MJ, D’Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011;30(10):1105–17. doi:10.1002/Sim.4154.
13. Pencina MJ, D’Agostino RB, Sr., D’Agostino RB, Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72; discussion 207–12. doi:10.1002/sim.2929.
14. Nalls MA, McLean CY, Rick J, et al. Diagnosis of Parkinson’s disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol. 2015;14(10):1002–9. doi:10.1016/S1474-4422(15)00178-7.
15. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol. 2008;63(2):167–73. doi:10.1002/ana.21291.
16. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Subjective complaints precede Parkinson disease: the rotterdam study. Arch Neurol. 2006;63(3):362–5. doi:10.1001/archneur.63.3.noc50312.
17. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 2015;14(1):57–64. doi:10.1016/S1474-4422(14)70287-X.
18. Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain. 2012;135(Pt 6):1860–70. doi:10.1093/brain/aws093.